Topic: Pioneering Strategies to Combat Drug Resistance in Prostate Cancer

Dear colleagues,

Prostate cancer is a prevalent malignancy in men globally. Advancements in research have bolstered survival rates for early-stage cancer. However, advanced-stage prostate cancer presents a significant challenge, with notably lower survival rates and a shorter average survival period. Despite progress in diagnostic and treatment methods, prostate cancer remains a leading cause of mortality worldwide. Current treatments for advanced-stage prostate cancer are hormone therapy and/or chemotherapy, which are often hindered by the development of drug resistance. Such resistance usually stems from various cellular mechanisms that undermine the efficacy of drugs. To address this challenge, it is crucial to advance already approved therapeutics that have demonstrated effectiveness against prostate cancer but are impeded by limitations in drug delivery, such as drug efflux, modulation of the tumor microenvironment, physiological and hormonal changes, etc. By leveraging the insights gleaned from these drugs regarding cellular processes in prostate cancer cells, treatment options can be repurposed to minimize their limitations. This thematic framework, "Pioneering Strategies to Combat Drug Resistance in Prostate Cancer," aims to compile manuscripts exploring novel strategies to discover and develop new modalities for combating drug resistance among prostate cancer patients, a common phenomenon. We welcome articles with a particular focus on elucidating state-of-the-art knowledge and future perspectives on emerging approaches to reversing drug resistance in prostate cancer and improving their clinical translation.

Prostate cancer, drug resistance, advanced-stage prostate cancer, novel therapy, chemotherapy, hormonal therapy, discovery & development, drug delivery outcomes

15 Jan 2025